PubRank

K Hoang-Xuan

Author PubWeight™ 64.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993 6.67
2 Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005 3.77
3 All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010 2.53
4 Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007 2.52
5 Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001 2.39
6 IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010 2.36
7 Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001 2.24
8 Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998 2.09
9 The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005 2.09
10 Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 1999 1.96
11 Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 2010 1.85
12 Supratentorial low-grade gliomas in older patients. Neurology 2009 1.55
13 Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009 1.48
14 Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001 1.47
15 Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 1995 1.35
16 Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 2001 1.34
17 Initial chemotherapy in gliomatosis cerebri. Neurology 2004 1.33
18 Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J 2001 1.29
19 OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001 1.19
20 EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005 1.18
21 Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 2004 1.14
22 Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999 1.09
23 Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 1995 1.07
24 Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br J Cancer 2013 0.96
25 Intravascular malignant lymphomatosis. Neuroradiology 2002 0.95
26 Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathol Appl Neurobiol 2009 0.93
27 Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer 2004 0.88
28 Summary version of the Standards, Options and Recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer 2003 0.86
29 MRI features of neurodegenerative Langerhans cell histiocytosis. Eur Radiol 2006 0.85
30 Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 1995 0.85
31 Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas. J Neurooncol 2000 0.85
32 Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 2005 0.84
33 Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 2000 0.83
34 Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 2008 0.83
35 Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer 1995 0.83
36 Treatment of malignant gliomas in the elderly. J Neurooncol 1999 0.83
37 TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 2009 0.83
38 Germline mutations of p53 but not p16/CDKN2 or PTEN/MMAC1 tumor suppressor genes predispose to gliomas. The ANOCEF Group. Association des NeuroOncologues d'Expression Française. Ann Neurol 1999 0.82
39 Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. J Neurooncol 2009 0.82
40 Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. Br J Cancer 2011 0.81
41 Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol 2005 0.81
42 P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurology 2000 0.81
43 Myoclonic encephalopathy after exposure to aluminum. Lancet 1996 0.80
44 Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1. Neurology 2003 0.79
45 alpha-Internexin expression identifies 1p19q codeleted gliomas. Neurology 2009 0.79
46 Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri. Neurology 2009 0.79
47 Seizure-related contrast enhancement of a ganglioglioma. Neurology 2002 0.78
48 Treatment of meningeal gliomatosis. J Neurooncol 1999 0.77
49 [Neurological damage of brain tumor therapy]. Rev Neurol (Paris) 2008 0.76
50 Neurofibromatosis type 2. Eur J Cancer 1994 0.76
51 [Neuro-oncology: a shifting speciality]. Rev Neurol (Paris) 2008 0.75
52 [Confrontation at Salpêtrière hospital. March 1992. Progressive amyotrophy of the upper limbs in a man with a 24 years course starting at age 29]. Rev Neurol (Paris) 1994 0.75
53 Analysis of the p21 gene in gliomas. J Neurooncol 1998 0.75
54 Genetic alterations in the chromosome 22q12 region associated with development of neuroectodermal tumors. Cold Spring Harb Symp Quant Biol 1994 0.75
55 [Editorial]. Rev Neurol (Paris) 2011 0.75
56 [Treatment of primary central nervous system lymphoma in the immunocompetent patient]. Rev Neurol (Paris) 2008 0.75
57 [Genes implicated in glial tumors]. Morphologie 2000 0.75
58 [Management of primary central nervous system lymphoma]. Rev Neurol (Paris) 2011 0.75
59 [The advantage of photon magnetic resonance spectroscopy in brain tumors]. Rev Neurol (Paris) 2008 0.75
60 [Biology and gene therapy of glioma]. Rev Prat 1996 0.75
61 [Molecular biology of oligodendroglial tumors]. Neurochirurgie 2005 0.75
62 A novel germline mutation of the PTEN/MMAC1 gene in a patient with Cowden disease. Acta Oncol 1999 0.75
63 [Treatment of dysimmune neuropathies with intravenous polyvalent human immunoglobulins]. Presse Med 1992 0.75
64 [Primary central nervous system lymphoma presenting with central neurogenic hyperventilation. A case report and review of the literature]. Rev Neurol (Paris) 2005 0.75
65 Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy. J Neurooncol 2013 0.75
66 Cerebral lymphoma in a patient with immunoglobulin paraproteinemic polyneuropathy. Muscle Nerve 1997 0.75